Aurinia Pharmaceuticals (AUPH) reported Q4 earnings Thursday of $0.01 per diluted share, swinging from a loss of $0.19 a year earlier.
Analysts polled by FactSet expected a loss of $0.02.
Revenue for the quarter ended Dec. 31 was $59.9 million, up from $45.1 million a year earlier.
Analysts surveyed by FactSet expected $60.1 million.
The company said it expects 2025 revenue of $250 million to $260 million.
Analysts polled by FactSet expect $274.4 million.